as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹3,494.5
Change
-37.8 (-1.07%)
Open
₹3,495.0
Prev. Close
₹3,532.3
Day High
₹3,533.0
Day Low
₹3,474.1
Volume Analysis
Traded
7,896
Delivered
4,372
Delivery %
55.37%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Promoter holding is rising
- •Strong operating margin (35.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (16.5%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,585.86 | ₹3,559.43 | ₹3,526.96 | ₹3,500.53 | ₹3,468.06 | ₹3,441.63 | ₹3,409.16 |
| Fibonacci | ₹3,559.43 | ₹3,536.93 | ₹3,523.03 | ₹3,500.53 | ₹3,478.03 | ₹3,464.13 | ₹3,441.63 |
| Camarilla | ₹3,510.7 | ₹3,505.3 | ₹3,499.9 | ₹3,500.53 | ₹3,489.1 | ₹3,483.7 | ₹3,478.3 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-23.39%
1 Week
-1.23%
1 Month
+4.1%
3 Months
-17.23%
6 Months
-26.2%
1 Year
-26.37%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
43.83%
Net margin 27.33% × asset turnover 0.79x × equity multiplier 2.03x
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.
TopFund Analysis
Sanofi Cons Healthc Ind L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 78/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (25/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (35.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
78/100 — GoodData confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Cash Flow
Corporate Governance
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Publication of Postal Ballot Notice in the newspapers is enclosed.
Postal ballot dispatched for RPT approvals with Opella India and Opella SAS, up to Rs. 5,301 million by 2027.
Copy of Newspaper Publication of Unaudited Financial Results for the quarter and nine months ended 30th September 2026 is enclosed.
Sanofi Consumer Healthcare India approved Q3 and nine-month FY26 results; Q3 revenue ₹2,631 million, profit ₹1,027 million.
Q3 FY26 revenue rose 12% to ₹2,631 million; nine-month revenue rose 16% to ₹7,280 million.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 | 263 |
| Expenses + | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | 146 | 161 |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | 89 | 102 |
| OPM % | 45.0% | 40.0% | 37.0% | 37.0% | 39.0% | 36.0% | 37.0% | 32.0% | 36.0% | 36.0% | 39.0% | 38.0% | 39.0% |
| Other Income + | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | 6 | 4 |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | 92 | 103 |
| Tax % | 25.0% | 24.0% | 25.0% | 25.0% | 26.0% | 29.0% | 25.0% | 23.0% | 25.0% | 27.0% | 25.0% | 25.0% | 25.0% |
| Net Profit + | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 | 77 |
| EPS in Rs | — | — | — | 13 | 20 | 19 | 22 | 26 | 27 | 29 | 29 | 30 | 33 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | -24 | -24 | -22 | 28 | 46 | 47 | 33 | 7 | 12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Dec 2023 (S) 8m | Dec 2024 (S) | Mar 2025 (S) | Dec 2025 (S) | |
|---|---|---|---|---|
| Sales + | 555 | 724 | 878 | 878 |
| Expenses + | 337 | 454 | 569 | 569 |
| Operating Profit | 219 | 271 | 309 | 309 |
| OPM % | 39.0% | 37.0% | 35.0% | 35.0% |
| Other Income + | 2 | -15 | 25 | 25 |
| Interest | 0 | 4 | 2 | 2 |
| Depreciation | 2 | 4 | 12 | 12 |
| Profit before tax | 219 | 247 | 320 | 320 |
| Tax % | 25.0% | 27.0% | 25.0% | 25.0% |
| Net Profit + | 165 | 181 | 240 | 240 |
| EPS in Rs | — | 79 | 104 | 104 |
| Dividend Payout % | 6.0% | 70.0% | 0.0% | 72.0% |
| Sales growth | — | 30 | 58 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Dec 2023 (S) | Dec 2024 (S) | Dec 2025 (S) | Jun 2026 (S) | |
|---|---|---|---|---|
| Reserves | 206 | 250 | 361 | 325 |
| Borrowings + | 0 | 20 | 25 | 21 |
| Other Liabilities + | 138 | 138 | 138 | 338 |
| Total Liabilities | 345 | 431 | 547 | 706 |
| Fixed Assets + | 5 | 29 | 36 | 30 |
| CWIP | 3 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets + | 338 | 402 | 511 | 677 |
| Total Assets | 345 | 431 | 547 | 706 |
| Equity Capital | 2 | 23 | 23 | 23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Dec 2023 (S) | Dec 2024 (S) | Mar 2025 (S) | Dec 2025 (S) | |
|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 439 | — | 175 |
| Cash from Investing Activity + | 0 | 2 | — | 8 |
| Cash from Financing Activity + | 2 | -116 | — | -134 |
| Net Cash Flow | 2 | 325 | — | 48 |
| Free Cash Flow | -4 | 429 | — | 167 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 2 | 208 | — | 85 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Public | 10.98% | 10.56% | 9.84% | 9.59% | 8.59% | 8.58% | 8.57% | 8.41% | 8.28% | 8.22% |
| Promoters | 60.4% | 60.4% | 60.4% | 60.4% | 71.27% | 71.27% | 71.27% | 71.27% | 71.27% | 71.27% |
| FII | 6.03% | 5.22% | 4.42% | 4.52% | 3.24% | 2.94% | 2.83% | 2.76% | 2.6% | 2.48% |
| DII | 22.6% | 23.83% | 25.35% | 25.48% | 16.89% | 17.21% | 17.33% | 17.57% | 17.85% | 18.03% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sanofi Cons Healthc Ind L (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 451,075 | 36.7 | 5.05 | 16.0% |
| Divi S Laboratories Ltd | 294,139 | 86.1 | 16.34 | 16.5% |
| Torrent Pharmaceuticals L | 177,632 | 81.8 | 9.67 | 27.4% |
| Apollo Hospitals Enter. L | 125,893 | 55.6 | 11.86 | 21.5% |
| Laurus Labs Limited | 125,380 | 93.6 | 20.73 | 18.3% |
| Zydus Lifesciences Ltd | 118,693 | 26.2 | 4.27 | 21.2% |
Which Mutual Funds Hold Sanofi Cons Healthc Ind L?
Frequently Asked Questions about Sanofi Cons Healthc Ind L
Sanofi Cons Healthc Ind L (SANOFICONR) closed at ₹3,494.5 on NSE on 19 November 2026, down 37.8 (1.07%) from the previous close.
Sanofi Cons Healthc Ind L trades on the NSE (National Stock Exchange of India) under the symbol SANOFICONR.
Sanofi Cons Healthc Ind L has a TopFund Quality Score of 78/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sanofi Cons Healthc Ind L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.